[A multicenter cooperative study on supplementary chemotherapy of uterocervical cancer. The Kyushu UFT Study Group of Uterocervical Cancer].
A randomized study was carried out by means of multicentered cooperation in respect to 5-FU and UFT administration, which was used as the supplementary chemotherapy after treatment of uterocervical cancer. Five years later, the improvement in prognosis was examined. Out of all the cases with radical operation + supplementary chemotherapy as well as with radical operation + postoperative radiotherapy + supplementary chemotherapy, 98 cases were ratable. The analysis of 98 cases led to no significant difference in the survival rate between the 5-FU administration group and the UFT administration group. As to the cases with supplementary chemotherapy + postoperative radiotherapy only, the survival rate was significantly higher in the UFT administration group than in the 5-FU administration group. During the administration, severe adverse side effects developed neither in the 5-FU administration group nor in the UFT administration group. These results suggest that UFT may be useful as a factor in supplementary chemotherapy of uterocervical cancer in combination with radiotherapy.
Kato
T
T
Dept. of Obstetrics and Gynecology, Kurume University School of Medicine.
Yakushiji
M
M
Yamabe
T
T
Sugimori
H
H
Hidaki
T
T
Tsukamoto
N
N
Tazaki
T
T
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy
D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil